Security key
N69605108
Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (PHVS)
CUSIP: N69605108
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Ordinary Shares, par value Euro 0.12 per share
- Total 13F shares
- 59,040,212
- Total 13F value
- $1,638,008,634
- Share change
- +393,245
- SEC-reported price per share
- $27.75
- Number of holders
- 107
- Value change
- +$19,048,600
- Number of buys
- 68
- Number of sells
- 21
- Shares outstanding
- 65,237,679
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q4 2025
Institutions
107
Top holders
10
PHVS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Pharvaris N.V. SEC filings
Pharvaris N.V. company facts
Broader feeds
Reporting periods
Holder history for CUSIP N69605108
Recent filing periods:
Ownership snapshot
Top reported holders of PHVS - Pharvaris N.V. - Ordinary Shares, par value Euro 0.12 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Venrock Healthcare Capita...
Disclosed value leader
GENERAL ATLANTIC, L.P.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 3.8%
13D/G row: Venrock Healthcare Capital Partners III, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Venrock Healthcare Capital Partners III, L.P. leads the comparable SEC ownership view at 3.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Venrock Healthcare Capital Partne...
3.8%
Bain Capital Life Sciences Fund, ...
2.5%
GENERAL ATLANTIC, L.P.
12%
FMR LLC
9.8%
Foresite Capital Management IV, LLC
7.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
3.8%
|
$51,436,214
2,047,620 shares
|
$0 | 30 Jun 2025 |
| Bain Capital Life Sciences Fund, L.P. |
13D/G
|
2.5%
|
$41,020,425
1,640,817 shares
|
-$5,670,300 | 31 Dec 2025 |
| GENERAL ATLANTIC, L.P. |
13F
Company
|
12%
|
$200,379,737
8,031,252 shares
|
— | 30 Sep 2025 |
| FMR LLC |
13F
Company
|
9.8%
|
$159,658,992
6,399,158 shares
|
— | 30 Sep 2025 |
| Foresite Capital Management IV, LLC |
13F
Company
|
7.3%
|
$119,225,596
4,778,581 shares
|
— | 30 Sep 2025 |
| venBio Partners LLC |
13F
Company
|
7.1%
|
$115,750,635
4,639,304 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
107
Shares
59,040,212
Rows available
107
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
83
Q4 2025 holders
107
Holder diff
24
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend